Social behaviour risk factors for drug resistant tuberculosis in mainland china: A meta-analysis

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 436-445

  Zhao, P ^a   Li, X J ^b   Zhang, S F ^a   Wang, X S ^c   Liu, C Y ^d  

^a Chaoyang Centre for Disease Control and Prevention   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d JILIN UNIVERSITY   (China)

Author keywords

Drug resistance; Meta analysis; Multidrug resistant tuberculosis; Risk factors; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AGE; ARTICLE; BIBLIOGRAPHIC DATABASE; CASE CONTROL STUDY; CHINA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; DIRECTLY OBSERVED THERAPY; DISEASE DURATION; DRUG RESISTANT TUBERCULOSIS; HEALTH CARE QUALITY; HUMAN; MEDLINE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; POVERTY; RISK ASSESSMENT; RISK FACTOR; SOCIAL BEHAVIOR; SYSTEMATIC REVIEW;

EID: 84860469092     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000205     Document Type: Article

References (44)

1. Gie R, International Union against Tuberculosis and Lung Disease (The Union): Diagnostic Atlas of Intrathoracic Tuberculosis in Children: a Guide for Low Income Countries. Paris: International Union Against Tuberculosis and Lung Disease (The Union), 2003.
2. World Health Organization: Global Tuberculosis Control: Epidemiology, Strategy, Financing: WHO Report 2009. Geneva: WHO, 2009; WHO/HTM/TB/2009.411.
3. World Health Organization: Multidrug and Extensively Drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva: WHO, 2010; WHO/HTM/TB/2010.3.
4. Ministry of Health of the People's Republic of China: Nationwide Anti-tuberculosis Drug Resistant Baseline Surveillance in China (2007 - 2008). Beijing: People's Public Health Press: 2010 [in Chinese].
5. Aziz M A, Wright A, Laszlo A, et al: Epidemiology of antituberculosis drug resistance (The Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368: 2142-2154.
6. Wright A, Bai G, Barrera L, et al: Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000 - 2004. MMWR 2006; 55: 301-305.
7. Gandhi N R, Moll A, Sturm A W, et al: Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
8. Faustini A, Hall AJ, Perucci CA: Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158-163.
9. Shen X, DeRiemer K, Yuan ZA, et al: Drug-resistant tuberculosis in Shanghai, China, 2000 - 2006: prevalence, trends, and risk factors. Int J Tuberc Lung Dis 2009; 13: 253-259.
10. Wei CY, Wang Q, Chen J: Study on risk factors for acquired drug resistant tuberculosis in some province. Mod Prev Med 2007; 34: 3275-3277 [in Chinese, English abstract].
11. Zhou LX: A Case-Control Study on Risk Factor for Acquired Drug Resistant Tuberculosis of Adult. MM Thesis, Guangxi Medical University, China, 2009.
12. Zhu JF, Wang WB, Wang XC, et al: Epidemic pattern of drug-resistant tuberculosis and its risk factors in Deqing County. Zhejiang J Prev Med 2009; 21: 6-8 [in Chinese, English abstract].
13. Zheng Z: Epidemiological Studies on the Prevalence Rate and the Impact Factors of Drug Resistant Tuberculosis Among Pulmonary Tuberculosis Inpatients. MM Thesis, Xiangya Medical College, Central South University, China, 2004.
14. Yang BF: Determinants and Molecular Epidemiology of Drug-resistant Tuberculosis in Rural Area of North Jiangsu Province. MD Dissertation, Fudan University, China, 2004.
15. Zhang H, Zhang A, Zhao P, et al: Analysis of the status and risk factors of drug resistant tuberculosis in Chaoyang District in Beijing. J Chin Antituberc Assoc 2009; 31: 218-222 [in Chinese, English abstract].
16. Lin H, Liu J, Chen L, et al: Drug resistance of tuberculosis from 2003 to 2006 in Chongqing. Acta Academiae Medicinae Militaris Tertiae 2008; 30: 1183-1185 [in Chinese, English abstract].
17. Chen J: Preliminary Study on Social Behavior Factors of TB Patients and Genotyping of Mycobacterium tuberculosis. MD Dissertation, Sichuan University, China, 2007.
18. Wang WH: Study of Risk Factors of Multi-drug Resistant Pulmonary Tuberculosis and the Quality of Life of Patients. MD Dissertation, Huazhong Science and Technology University, China, 2005.
19. World Health Organization: WHO Report on the Tuberculosis Epidemic, 1995. Stop TB at the Source. Geneva: WHO, 1995; Report No. WHO/TB/95.183.
20. Yang X, Li Y, Wen X, et al: Risk factors for drug resistance in pulmonary tuberculosis inpatients. J Evid Based Med 2010; 3: 162-167.
21. Li H, Yan CL, Zhu SJ, et al: Risk factors of multidrug-resistant tuberculosis. J Clin Pulm Med 2010; 15: 367-368 [in Chinese, English abstract].
22. Xu B, Hu Y, Wang WB, et al: Molecular-epidemiological study on the transmission of drug resistant tuberculosis and its influencing factors in rural areas of eastern China. Zhonghua Liu Xing Bing Xue Za Zhi 2010; 31: 525-529.
23. Zhang M, Lou P, Liu L, et al: Drug resistance and its influencing factors among patients with multidrug-resistant tuberculosis. Chin J Public Health 2010; 26: 1439-1440 [in Chinese, English abstract].
24. Xu L, Yang Z, Lv DL, et al: Analysis of the situation of anti-TB drug resistance and its risk factors in Shenzhen City. China Trop Med 2010; 10: 1333-1335 [in Chinese, English abstract].
25. Sun B, Hu Y, Zhu FD, et al: Prevalence and analysis of the multidrug-resistant tuberculosis factors in rural areas of north Jiangsu. Chin Prim Health Care 2008; 22: 66-68 [in Chinese, English abstract].
26. Pritchard AJ, Hayward AC, Monk PN, et al: Risk factors for drug resistant tuberculosis in Leicestershire - poor adherence to treatment remains an important cause of resistance. Epidemiol Infect 2003; 130: 481-483.
27. Moniruzzaman A, Elwood RK, Schulzer M, et al: A population-based study of risk factors for drug resistant TB in British Columbia. Int J Tuberc Lung Dis 2006; 10: 631-638.
28. Espinal MA, Laserson K, Camacho M, et al: Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5: 887-893.
29. Law WS, Yew WW, Chiu Leung C, et al: Risk factors for multidrug-resistant tuberculosis in Hong Kong. Int J Tuberc Lung Dis 2008; 12: 1065-1070.
30. Mitchison DA: How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
31. Pablos-Méndez A, Raviglione MC, Laszlo A, et al: Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization - International Union against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338: 1641-1649.
32. World Health Organization: Anti-tuberculosis Drug Resistance in the World, Report No. 3. Geneva: WHO, 2004; WHO/HTM/TB/2004.343.
33. Cox HS, Morrow M, Deutschmann PW: Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008; 336: 484-487.
34. World Health Organization: The Stop TB Strategy: Building on and Enhancing DOTS to Meet the TB-related Millennium Development Goals. Geneva: WHO, 2006; WHO/HTM/STB/2006.37.
35. Frieden TR, Fujiwara PI, Washko RM, et al: Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
36. Munsiff SS, Li J, Cook SV, et al: Trends in drug-resistant Mycobacterium tuberculosis in New York City, 1991-2003. Clin Infect Dis 2006; 42: 1702-1710.
37. DeRiemer K, García-García L, Bobadilla-del-Valle M, et al: Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245.
38. Yew WW: Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Chemotherapy 1999; 45(suppl 2): 26-33.
39. Zhang LX, Tu DH, Enarson DA: The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing. Int J Tuberc Lung Dis 2000; 4: 904-910.
40. Liu YN, Hou M, Wang W, et al: Investigation of impact factors for chemotherapy compliance of tuberculosis patients in Beijing. J Capital Med Univ 2011; 32: 125-128 [in Chinese, English abstract].
41. National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis: Report on Fourth National Epidemiological Sampling Survey of Tuberculosis. Chin J Tuberc Respir Dis 2002; 25: 3-7 [in Chinese, English abstract].
42. Marahatta SB: Multi-drug resistant tuberculosis burden and risk factors: an update. Kathmandu Univ Med J (KUMJ) 2010; 8: 116-125.
43. Keshavjee S, Gelmanova IY, Pasechnikov AD, et al: Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann NY Acad Sci 2008; 1136: 1-11.
44. Tacconelli E, Cataldo MA: Identifying risk factors for infections: the role of meta-analyses. Infect Dis Clin North Am 2009; 23: 211-224.